Oral Medication for Ventricular Tachycardia with Increased QT Interval
First-Line Therapy: Beta Blockers
- The European Society of Cardiology recommends beta blockers as the treatment of choice for patients with ventricular tachycardia (VT) and prolonged QT interval, as they reduce mortality in patients with recurrent polymorphic VT 1
- Beta blockers decrease sympathetic stimulation that can trigger arrhythmias in patients with VT and QT prolongation 2
- The European Heart Society specifically recommends beta blockers for patients with torsades de pointes, a form of polymorphic VT associated with QT prolongation 1, 2
Medication Selection Algorithm
- The American Heart Association recommends beta blockers as the first choice for all patients with VT and QT prolongation, as they are particularly effective for preventing recurrent episodes 1, 2, 4
- Beta blockers should be initiated during hospitalization and continued thereafter for long-term management of VT and QT prolongation 3
- Mexiletine may be considered as a second choice for patients with LQT3 subtype and torsades de pointes, as it acts as a sodium channel blocker similar to lidocaine but in oral form 1
Important Considerations
- The American College of Cardiology recommends correcting any electrolyte abnormalities, especially potassium, and withdrawing any QT-prolonging medications to manage QT prolongation 1, 5
- Cardiac pacing should be considered if bradycardia is present in patients with QT prolongation 1
- Lidocaine is most effective for VT associated with acute myocardial ischemia, but oral beta blockers are superior for long-term management 1, 2, 3, 6, 7
Special Situations
- For patients with frequent recurrences despite beta blocker therapy, radiofrequency catheter ablation followed by ICD implantation may be considered, as recommended by the European Heart Rhythm Association 3
- Transvenous catheter overdrive pacing may be considered if VT is frequently recurrent and catheter ablation is not possible, according to the European Society of Cardiology 3
- Beta blockers remain first-line therapy for patients with concomitant structural heart disease, and Class IC antiarrhythmics should be avoided, as recommended by the American Heart Association 3, 4, 8
Monitoring Recommendations
- Careful monitoring of electrolytes, particularly potassium and magnesium, is recommended for patients with VT and QT prolongation, as suggested by the European Society of Cardiology 1